Physician profile
Peter Jay Cleavinger
NPI 1841244191
$5,377.38
in general payments reported to CMS, 2019-2025
35 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $241 · 2022: $767 · 2023: $1,473 · 2024: $957 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,363.85 |
| Education | $145.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,233.43 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Janssen Biotech, INC. | $945.49 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $394.24 | 2019-2025 | |
| Celgene Corporation | $289.80 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $210.21 | 2019-2025 | Entyvio |
| Amgen INC. | $201.42 | 2022-2023 | Avsola, Amjevita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.66 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Cook Medical LLC | $189.55 | 2019-2023 | Hemospray |
| Lilly USA, LLC | $185.77 | 2023-2025 | Omvoh |
| Allergan, INC. | $184.30 | 2019-2020 | |
| Genzyme Corporation | $130.53 | 2023-2025 | |
| Celltrion USA INC. | $125.05 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $120.88 | 2019-2023 | Dificid |
| Mauna Kea Technologies, INC. | $117.12 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $94.95 | 2022-2025 | Ocaliva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $93.66 | 2019 | |
| Phathom Pharmaceuticals, INC. | $81.62 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $65.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $63.30 | 2022-2023 | Renflexis, Hadlima |
| Ipsen Biopharmaceuticals, INC | $51.08 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $50.48 | 2023 | Rebyota, Clenpiq |
| Ardelyx, INC. | $47.49 | 2023-2024 | Ibsrela |
| Medtronic, INC. | $45.01 | 2024 | Interstim |
| Qol Medical, LLC | $37.18 | 2019-2025 | Sucraid |
| Gilead Sciences, INC. | $35.13 | 2023-2024 | |
| Ucb, INC. | $29.64 | 2019 | |
| Novo Nordisk INC | $29.36 | 2025 | Wegovy |
| Ethicon US, LLC | $26.87 | 2023 | Linx Reflux Management System |
| Ironwood Pharmaceuticals, INC | $26.22 | 2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $19.56 | 2022 | |
| Fresenius Kabi USA, LLC | $16.61 | 2023 | Smoflipid |
| Nestle Healthcare Nutrition INC. | $15.89 | 2022 | |
| Shire North American Group INC | $14.51 | 2019 | |
| Glaxosmithkline, LLC. | $13.43 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Cleavinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.